Epizyme Inc. (EPZM) Hits New 52-Week Low at $7.14
Epizyme Inc. (NASDAQ:EPZM)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $7.14 and last traded at $7.33, with a volume of 153,547 shares traded. The stock had previously closed at $7.58.
A number of brokerages have recently issued reports on EPZM. Leerink Swann reissued an “outperform” rating and set a $39.00 target price on shares of Epizyme in a research note on Tuesday, June 21st. Zacks Investment Research raised Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday, August 10th. JMP Securities reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research note on Thursday, June 23rd. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Epizyme in a research note on Monday, May 9th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Monday, June 20th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.11.
The company’s 50 day moving average price is $9.10 and its 200 day moving average price is $10.33. The company’s market cap is $423.66 million.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, equities analysts forecast that Epizyme Inc. will post ($2.19) earnings per share for the current year.
In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total value of $40,120.00. Following the transaction, the insider now owns 4,000 shares of the company’s stock, valued at $40,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.